Text Version
Entrez PubMed Overview Help | FAQ Tutorial New/Noteworthy E-Utilities
PubMed Services Journals Database MeSH Database Single Citation Matcher Batch Citation Matcher Clinical Queries LinkOut Cubby
Related Resources Order Documents NLM
Gateway TOXNET Consumer
Health Clinical Alerts ClinicalTrials.gov PubMed
Central
Privacy Policy
|
|
-
-
Drug-induced pneumonitis
and heart failure simultaneously associated with
venlafaxine.
Drent M, Singh S, Gorgels AP, Hansell
DM, Bekers O, Nicholson AG, van Suylen RJ, du Bois
RM.
Department of Respiratory Medicine, University Hospital
of Maastricht, P.O. Box 5800, 6202 AZ Maastricht, The Netherlands.
mdr@slon.azm.nl
Two cases of interstitial pneumonia with cardiac
failure developing in patients treated with the new antidepressant
venlafaxine are presented. A strong relationship between the development
of the patients' illness and the initiation of venlafaxine treatment was
identified. The cytochrome P (CYP) 450 system is involved in the
metabolism of venlafaxine, suggesting that alterations in the drug
metabolic clearance might be, at least in part, responsible for the
development of drug-induced damage in these cases. This might occur
either as a consequence of a genetic factor or concomitant drug therapy
with an inhibitor of the related CYP system. After identifying the
causative agent in the first case, withdrawal of the antidepressant
together with corticosteroid treatment led to a favorable outcome. In
the other case, the multiorgan failure became fatal. These cases
highlight a hitherto undescribed association of an adverse lung reaction
and heart failure due to venlafaxine.
Publication Types:
PMID: 12663337 [PubMed - indexed for
MEDLINE]
|